Drug news
FDA approves Binosto (EffRx) for Osteoporosis
The FDA has approved Binosto (alendronate sodium) Effervescent Tablets, previously known as EX101, for the treatment of Osteoporosis in postmenopausal women, and as a treatment to increase bone mass in men with Osteoporosis. EffRx anticipates that Binosto will be commercially available in the United States in the third quarter of 2012. Binosto was developed by EffRx based on an agreement with Merck & Co granting EffRx the worldwide rights to all effervescent and related patents of Fosamax (alendronate). Patents have been granted to EffRx providing exclusivity for Binosto through February 2023. Additional patents are pending.